NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Breast Cancer Elevate the 21-Gene (Oncotype DX Breast Recurrence Score) Test as the Only Preferred Multigene Test to Predict Chemotherapy Benefit

Node-Negative: Chemotherapy Benefit

Updated NCCN Guidelines® from the National Comprehensive Cancer Network® (NCCN®) underscore the unique advantage of the 21-gene (Oncotype DX) test as the only preferred multi-gene test to determine chemotherapy benefit for patients with node-negative early-stage breast cancer.
(See page BINV-6 in the Guidelines.)

Node-Positive: Inclusion in the Algorithm

Additionally, the NCCN Guidelines elevated multi-gene assays, including the 21-gene (Oncotype DX) test into the algorithm to consider for assessing prognosis and determining chemotherapy benefit for patients with micrometastases and 1–3 positive nodes.
(See page BINV-7 in the Guidelines.)


Get the Guidelines

Genomic Health Comments on the Guidelines

Read our official press release on the significance of these updated guidelines.


Read Press Release



Backed by clinical data

The landmark TAILORx trial results provide definitive answers


Learn more

REFERENCE

1. NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines® V3.2018.

 

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™